Skip to main content

SB203580

BML-EI286

82 citations

  • BML-EI286-0001   —   1 mg
    $119.00
  • BML-EI286-0005   —   5 mg
    $486.00

Cell permeable, specific inhibitor of p38 (SAPK2a). Inhibits p38 MAPK stimulation of MAPKAPK2 (IC50=70nM). Can inhibit the key cell cycle event of retinoblastoma protein phosphorylation in interleukin-2-stimulated T cells. Studies on the proximal regulator of this event, the PI(3)K (phosphoinositide 3-kinase)/Akt (protein kinase B; PKB) pathway, showed that SB203580 blocks the phosphorylation and activation of Akt by inhibiting the Akt kinase, phosphoinositide-dependent protein kinase 1 (PDK1).

The concentrations of SB203580 required to block Akt phosphorylation (IC50= 3-5µM) are only approximately 10-fold higher than those required to inhibit p38 MAP kinase (IC50=0.3-0.5µM). These data define a new activity for this drug and suggest that extreme caution should be used when interpreting data when SB203580 has been used at concentrations above 1-2µM. Non-specific effects include inhibition of COX-1 and -2. Enhances clonal growth of skin epithelial progenitor cells and stimulates neural stem cell proliferation.

Shipping: Available products typically ship within 24/48h, via priority shipping.

Do you need support? Contact Customer Service or Technical Support.

Online Account
Access or Create Your Account


Regulatory Status

RUO – Research Use Only